Wash your hands often, and shower daily
Trial design: 751 adults with obesity (BMI 30, or 27 with at least one comorbidity) No type 2 diabetes 72-week follow-up Tirzepatide 10mg or 15mg vs Semaglutide 2.4mg Results at 72 weeks: When looking at tirzepatide weight loss results from SURMOUNT-5 alongside semaglutide weight loss results from the STEP trials, the gap is consistent and statistically significant across every subgroup sex, age, baseline BMI, and presence of metabolic comorbidities
It is believed that Semaglutide will bring more surprises to people as the trial proceeds
In addition, PYY(3-36) promotes weight loss by suppressing appetite and delaying gastric emptying, thus improving insulin resistance
One of the latest advancements combines GLP-1 agonists with probiotics
Individual circumstances: While guidelines are in place, a doctor is ultimately responsible for making decisions appropriate for each patient